Publications by authors named "Mohamed Fejjal"
Article Synopsis
- The study focused on determining the best type of anticoagulation therapy for COVID-19 pneumonia patients to reduce mortality and disease duration, comparing therapeutic anticoagulation (TA), high-dose prophylactic anticoagulation (HD-PA), and standard-dose prophylactic anticoagulation (SD-PA).
- Conducted in France, the ANTICOVID trial involved 334 patients with hypoxemic COVID-19 pneumonia, all requiring supplemental oxygen, and aimed to understand the effects of these treatments over a 14-day period.
- Results indicated that HD-PA and SD-PA had similar outcomes, as did TA when compared to SD-PA, suggesting no significant advantage for either anticoagulation strategy in improving patient outcomes by day
Introduction: COVID-19 induces venous, arterial and microvascular thrombosis, involving several pathophysiological processes. In patients with severe COVID-19 without macrovascular thrombosis, escalating into high-dose prophylactic anticoagulation (HD-PA) or therapeutic anticoagulation (TA) could be beneficial in limiting the extension of microvascular thrombosis and forestalling the evolution of lung and multiorgan microcirculatory dysfunction. In the absence of data from randomised trials, clinical practice varies widely.
View Article and Find Full Text PDF